Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s share price rose 5.7% during mid-day trading on Wednesday . The company traded as high as $19.39 and last traded at $19.76. Approximately 31,567 shares traded hands during trading, a decline of 84% from the average daily volume of 193,123 shares. The stock had previously closed at $18.70.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on SEPN shares. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price target for the company. TD Cowen initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a "buy" rating for the company. Cantor Fitzgerald initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 target price on the stock. Finally, Wells Fargo & Company started coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target for the company.
Check Out Our Latest Stock Analysis on Septerna
Septerna Price Performance
The stock's 50 day moving average is $22.57.
Insider Transactions at Septerna
In other news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the firm's stock in a transaction on Monday, October 28th. The stock was purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC purchased a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,095 shares of the company's stock, valued at approximately $185,000.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
